NCT04818632 - AZD9833 China PK Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions

ER+, HER2-, Metastatic Breast Cancer

Interventions

DRUG

AZD9833

Part A: AZD9833 monotherapy dose escalation.

DRUG

AZD9833

Part B: AZD9833 monotherapy dose expansion

DRUG

AZD9833 with palbociclib

Part B: AZD9833 with palbociclib dose expansion

DRUG

AZD9833 with everolimus

Part B: AZD9833 with everolimus dose expansion

Trial Locations (4)

Research Site, Beijing

Research Site, Shanghai

Research Site, Wuhan

Research Site, Chengdu